This Article Full Text Full Text (PDF) All Versions of this Article: 36/10/2321    most recent 01.STR.0000179041.80222.dcv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kase, C. S. Search for Related Content PubMed PubMed Citation Articles by Kase, C. S.

(Stroke. 2005;36:2321.)
© 2005 American Heart Association, Inc.

Emerging Therapies

Hemostatic Treatment in the Early Stage of Intracerebral Hemorrhage

The Recombinant Factor VIIa Experience

From the Department of Neurology, Boston University School of Medicine, Boston, Mass.

Correspondence to Carlos S. Kase, MD, Department of Neurology, Boston University School of Medicine, 715 Albany St, C-329, Boston, MA 02118. E-mail cskase@bu.edu

Section Editors: Marc Fisher MD Antoni Dá valos MD

An extract of the first 250 words of the full text is provided, because this article has no abstract.

The treatment of intracerebral hemorrhage (ICH) has been a largely neglected item. In contrast to literally dozens of clinical trials of treatment of ischemic stroke, only a handful have addressed treatment of ICH with either medical (steroids,¹ osmotic diuretics²) or surgical³ interventions. The medical intervention trials, primarily aimed at reducing brain edema surrounding the ICH, have shown lack of benefit of treatment with dexamethasone¹ or glycerol solutions.² Although some pilot data suggested a potential benefit of early surgical drainage of the hematoma,^4,5 the recent publication of neutral results in the large, prospective, and randomized international Surgical Trial in Intracerebral Hemorrhage (STICH) study⁶ has been a disappointment. Mendelow and colleagues went for 8 years of enrollment and follow up of over 500 subjects in each treatment group, one managed "conservatively," the other subjected to surgical drainage of the hematoma within a maximum of 4 days from symptom onset. The final results showed no benefit of one mode of treatment over the other, because a favorable outcome occurred as frequently in the "conservative" (24%) as in the surgical (26%) group when they were evaluated at 6 months. Although a prespecified subgroup analysis suggested a possible advantage of surgical treatment for superficially located (1 cm from the cortical surface) lobar hematomas, the overall trial results showed that only one fourth of patients with ICH can be expected to have a good clinical outcome, which cannot be improved on by surgical treatment.

In the wake of the neutral STICH trial results, it . . . [Full Text of this Article]

This article has been cited by other articles:

				J. D. Sturgeon, A. R. Folsom, W.T. Longstreth Jr, E. Shahar, W. D. Rosamond, and M. Cushman Hemostatic and Inflammatory Risk Factors for Intracerebral Hemorrhage in a Pooled Cohort Stroke, August 1, 2008; 39(8): 2268 - 2273. [Abstract] [Full Text] [PDF]

				W. K. Hoots Challenges in the Therapeutic Use of a "So-Called" Universal Hemostatic Agent: Recombinant Factor VIIa Hematology, January 1, 2006; 2006(1): 426 - 431. [Abstract] [Full Text] [PDF]